Correlation Between Centessa Pharmaceuticals and Mink Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Centessa Pharmaceuticals and Mink Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Centessa Pharmaceuticals and Mink Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Centessa Pharmaceuticals PLC and Mink Therapeutics, you can compare the effects of market volatilities on Centessa Pharmaceuticals and Mink Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Centessa Pharmaceuticals with a short position of Mink Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Centessa Pharmaceuticals and Mink Therapeutics.

Diversification Opportunities for Centessa Pharmaceuticals and Mink Therapeutics

-0.15
  Correlation Coefficient

Good diversification

The 3 months correlation between Centessa and Mink is -0.15. Overlapping area represents the amount of risk that can be diversified away by holding Centessa Pharmaceuticals PLC and Mink Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mink Therapeutics and Centessa Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Centessa Pharmaceuticals PLC are associated (or correlated) with Mink Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mink Therapeutics has no effect on the direction of Centessa Pharmaceuticals i.e., Centessa Pharmaceuticals and Mink Therapeutics go up and down completely randomly.

Pair Corralation between Centessa Pharmaceuticals and Mink Therapeutics

Given the investment horizon of 90 days Centessa Pharmaceuticals PLC is expected to generate 1.46 times more return on investment than Mink Therapeutics. However, Centessa Pharmaceuticals is 1.46 times more volatile than Mink Therapeutics. It trades about 0.02 of its potential returns per unit of risk. Mink Therapeutics is currently generating about -0.12 per unit of risk. If you would invest  1,646  in Centessa Pharmaceuticals PLC on September 15, 2024 and sell it today you would earn a total of  11.00  from holding Centessa Pharmaceuticals PLC or generate 0.67% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Centessa Pharmaceuticals PLC  vs.  Mink Therapeutics

 Performance 
       Timeline  
Centessa Pharmaceuticals 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Centessa Pharmaceuticals PLC are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Centessa Pharmaceuticals is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.
Mink Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Mink Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's forward-looking signals remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Centessa Pharmaceuticals and Mink Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Centessa Pharmaceuticals and Mink Therapeutics

The main advantage of trading using opposite Centessa Pharmaceuticals and Mink Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Centessa Pharmaceuticals position performs unexpectedly, Mink Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mink Therapeutics will offset losses from the drop in Mink Therapeutics' long position.
The idea behind Centessa Pharmaceuticals PLC and Mink Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Other Complementary Tools

My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
CEOs Directory
Screen CEOs from public companies around the world
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope